Cases of Myocarditis Reported in Teens Receiving Pfizer Vaccine in the US

Myocarditis Occurrence Study Published in the American Academy of Pediatrics (AAP) Journal

Cases of myocarditis have been reported in teenagers who received Pfizer's COVID-19 vaccine in the United States.

According to the Associated Press, a paper was published online on the 4th (local time) in the American Academy of Pediatrics (AAP) journal reporting that seven male adolescents aged 14 to 17 in the U.S. developed myocarditis after receiving the Pfizer vaccine in April and May.

Myocarditis is a disease in which inflammation occurs in the heart muscle due to a virus and can also occur after being infected with COVID-19. Adolescents who experienced myocarditis reported chest pain within a few days after vaccination. However, all were discharged from the hospital within 2 to 6 days, and there were no severe cases.

The journal stated that further investigation is needed regarding cases of myocarditis in teenage vaccine recipients but explained that the benefits of vaccination outweigh any potential risks. This consideration takes into account that over 4 million COVID-19 infections have occurred among U.S. adolescents under 18, with more than 300 deaths among them.

In this regard, the U.S. Centers for Disease Control and Prevention (CDC) announced on the 27th of last month that they are monitoring reports of myocarditis occurring in teenagers and young adults who received messenger RNA (mRNA) vaccines such as the Pfizer vaccine.

Previously, cases of young men showing myocarditis symptoms after receiving the Pfizer COVID-19 vaccine were also reported in Israel. On the 1st, the Israeli Ministry of Health explained that among 5 million people vaccinated against COVID-19 from December last year to this month, 275 showed symptoms of myocarditis.

This content was produced with the assistance of AI translation services.